AesMed Participation in KIMES 2025 Featured in Industry News

We are pleased to share that AesMed participation in KIMES 2025 has been recently featured in leading industry media. The article highlights our commitment to innovation in the field of hair loss treatment, particularly through our flagship AGF39™ mesotherapy solution.

The report introduces AGF39™ as a scientifically validated cytokines-based therapy for alopecia, widely adopted in over 500 clinics across Korea, Japan, and China. It also acknowledges our clinical research achievements, which have been presented at major academic conferences such as the World Congress of Hair Research and published in SCI-indexed journals.

Through this coverage, AesMed global reputation as a pioneer in hair mesotherapy solutions continues to grow. We are honored to be recognized for our contributions and will continue to advance innovative treatments that improve the lives of hair loss sufferers worldwide.

⇒ Read the full article here (KR)